drugset / Trial / NCT01882491

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

NCT01882491

Phase 2 Completed 91 enrolled XOMA (US) LLC
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of inflammatory erosive osteoarthritis of the hand.

Timeline

Start
2013-05
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject gevokizumab Monoclonal antibody Subcutaneous

Indications